

# Hailing Cheng

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9588583/publications.pdf>

Version: 2024-02-01

17  
papers

2,940  
citations

623188

14  
h-index

887659

17  
g-index

18  
all docs

18  
docs citations

18  
times ranked

5734  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | BTF3 confers oncogenic activity in prostate cancer through transcriptional upregulation of Replication Factor C. <i>Cell Death and Disease</i> , 2021, 12, 12.   | 2.7  | 12        |
| 2  | Melatonin potentiates the cytotoxic effect of Neratinib in HER2+ breast cancer through promoting endocytosis and lysosomal degradation of HER2. <i>Oncogene</i> , 2021, 40, 6273-6283.                           | 2.6  | 18        |
| 3  | Induction of EnR stress by Melatonin enhances the cytotoxic effect of Lapatinib in HER2-positive breast cancer. <i>Cancer Letters</i> , 2021, 518, 82-93.  | 3.2  | 16        |
| 4  | Targeting the EphB4 receptor tyrosine kinase sensitizes HER2-positive breast cancer cells to Lapatinib. <i>Cancer Letters</i> , 2020, 475, 53-64.  | 3.2  | 17        |
| 5  | Inhibition of SGK1 confers vulnerability to redox dysregulation in cervical cancer. <i>Redox Biology</i> , 2019, 24, 101225.   | 3.9  | 23        |
| 6  | MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer. <i>EBioMedicine</i> , 2019, 43, 225-237.  | 2.7  | 48        |
| 7  | Inhibition of BTF3 sensitizes luminal breast cancer cells to PI3K inhibition through the transcriptional regulation of ER. <i>Cancer Letters</i> , 2019, 440-441, 54-63.   | 3.2  | 25        |
| 8  | Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF- $\kappa$ B signaling. <i>Cell Death and Disease</i> , 2018, 9, 809.                                      | 2.7  | 26        |
| 9  | PI3K-p110 mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 7095-7100. | 3.3  | 75        |
| 10 | Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes. <i>Gynecologic Oncology</i> , 2016, 142, 548-556.  | 0.6  | 80        |
| 11 | PI3K/AKT Signaling Regulates H3K4 Methylation in Breast Cancer. <i>Cell Reports</i> , 2016, 15, 2692-2704.   | 2.9  | 92        |
| 12 | Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer. <i>Oncotarget</i> , 2016, 7, 13153-13166.  | 0.8  | 66        |
| 13 | Chemopreventive effects of aspirin at a glance. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1855, 254-263.   | 3.3  | 26        |
| 14 | A Genetic Mouse Model of Invasive Endometrial Cancer Driven by Concurrent Loss of Pten and Lkb1 Is Highly Responsive to mTOR Inhibition. <i>Cancer Research</i> , 2014, 74, 15-23.                               | 0.4  | 57        |
| 15 | Abstract A007: Mutant PIK3CA accelerates HER2-driven transgenic mammary tumor progression, enhances cancer stem cell features, and induces resistance to combinations of anti-HER2 therapies. , 2013, , .        |      | 0         |
| 16 | SIK1 Couples LKB1 to p53-Dependent Anoikis and Suppresses Metastasis. <i>Science Signaling</i> , 2009, 2, ra35.  | 1.6  | 137       |
| 17 | Targeting the phosphoinositide 3-kinase pathway in cancer. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 627-644.  | 21.5 | 2,218     |